{"url_path":"/sec/cldx/8-k/2026-06-26/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/744218/0001104659-26-078023-index.html","accession_number":"0001104659-26-078023","cik":"0000744218","ticker":"CLDX","issuer_name":"Celldex Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/744218/0001104659-26-078023-index.html","primary_entity_key":"0000744218","primary_entity_name":"Celldex Therapeutics, Inc."},"word_count":89,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\nExhibit No.\n \nDescription\n\n \n \n \n\n[10.1](tm2619009d1_ex10-1.htm)\n \n[Amendment No. 4 to Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan](tm2619009d1_ex10-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n-3-\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**CELLDEX THERAPEUTICS, INC.**\n\n \n \n\nDated: June 26, 2026\nBy:\n*/s/ Sam Martin*\n\n \nName:\nSam Martin\n\n \nTitle:\nSenior Vice President and Chief Financial Officer\n\n \n\n-4-"}